Toggle light / dark theme

😀


JERUSALEM, Dec 11 (Reuters) — Israeli researchers said on Saturday they found that a three-shot course of the Pfizer/BioNTech (PFE.N), (22UAy. DE) COVID-19 vaccine provided significant protection against the new Omicron variant.

The findings were similar to those presented by BioNTech and Pfizer earlier in the week, which were an early signal that booster shots could be key to protect against infection from the newly identified variant.

The study, carried out by Sheba Medical Center and the Health Ministry’s Central Virology Laboratory, compared the blood of 20 people who had received two vaccine doses 5–6 months earlier to the same number of individuals who had received a booster a month before.

The US Navy announced it tested anti-submarine laser weapons in the Gulf of Aden — report.

#news #trending #currentevents.

Freedom over censorship, truth over narrative.
Follow us on Facebook: https://www.facebook.com/RTnews.
Follow us on TikTok: https://www.tiktok.com/@rt.news.
Follow us on Telegram: t.me/rtnews.
Follow us on Twitter: https://twitter.com/RT_com

Elon Musk, the billionaire CEO of Tesla, is defending himself once again against public criticism. It is time for Tesla CEO Elon Musk to answer to questions regarding his income tax bill.

“If you opened your eyes for two seconds, you would know that I will pay more taxes than any American in history this year.” Musk tweeted earlier this week.

Tesla CEO Elon Musk tweeted a reaction to Massachusetts Sen. Elizabeth Warren’s criticism of him as Time Magazine’s Person of the Year for not paying his taxes.

Viewers like you help make PBS (Thank you 😃). Support your local PBS Member Station here: https://to.pbs.org/DonateSPACE

It turns out that “nothing” is one of the most interesting somethings in all of physics. Signup for your free trial to The Great Courses Plus here: http://ow.ly/OOOp30beNyt.

Note: There is a correction in this video that has been addressed in the pinned comment below.

You can further support us on Patreon at https://www.patreon.com/pbsspacetime.

A documentary exploring how artificial intelligence is changing life as we know it — from jobs to privacy to a growing rivalry between the U.S. and China.

FRONTLINE investigates the promise and perils of AI and automation, tracing a new industrial revolution that will reshape and disrupt our world, and allow the emergence of a surveillance society.

This journalism is made possible by viewers like you. Support your local PBS station here: http://www.pbs.org/donate.

Love FRONTLINE? Find us on the PBS Video App where there are more than 250 FRONTLINE documentaries available for you to watch any time: https://to.pbs.org/FLVideoApp.

Elon Musk has announced a new timeframe for his massive Mars project, and it is a lot closer than you would believe.

In an article published Monday, Musk said, ‘I’ll be surprised if we’re not landing on Mars within five years.

Musk, the 50-year-old SpaceX founder and CEO who was selected Time’s Person of the Year, has grandiose ambitions for Mars: a self-sustaining metropolis with solar-powered hydroponic fields where people may live indefinitely, 34 million miles from Earth.

Boston-based biotech Vincere Biosciences is on a mission to combat neurodegenerative disease by improving the quality of the mitochondria in our cells. The company was spun out from AI drug discovery company NeuroInitiative in 2018 after its platform identified that modulation of certain enzymes to repair mitochondrial health “may slow or stop the progression of Parkinson’s disease and other age-related disorders.”

In addition to seed funding, Vincere has received grants from the National Institutes of Health and Michael J Fox Foundation, and the company is now gearing up for a Series A funding round in early 2022.

Longevity. Technology: Mitochondria’s role in longevity is a hot topic. Often referred to as the “powerhouse of the cell”, these miniature organs within our cells play a key role in providing the energy needed for growth, repair and rejuvenation. As we age, our mitochondria begin to decline in function, and this decline is linked to a range of age-related diseases. We caught up with Vincere’s co-founder and CEO Dr Spring Behrouz to find out how her company aims to tap into the potential of these small but mighty biological players.